BSE: 530125 | NSE: | Pharmaceuticals & Drugs | Small Cap
Past 10 year's financial track record analysis by Moneyworks4me indicates that Samrat Pharmachem Ltd is a average quality company.
The key valuation ratios of Samrat Pharmachem Ltd's currently when compared to its past seem to suggest it is in the Fair zone.
The Price Trend analysis by MoneyWorks4Me indicates it is Weak which suggest that the price of Samrat Pharmachem Ltd is likely to Fall in the short term. However, please check the rating on Quality and Valuation before investing.
Data adjusted to bonus, split, extra-ordinary income, rights issue and change in financial year end.
| Mar'15 | Mar'16 | Mar'17 | Mar'18 | Mar'19 | Mar'20 | Mar'21 | Mar'22 | Mar'23 | Mar'24 | TTM | |
|---|---|---|---|---|---|---|---|---|---|---|---|
| ROCE % ⓘ | 6.5% | 5.3% | 16.4% | 23.1% | 11.8% | 22.4% | 23.9% | 52.3% | 34.9% | 4.1% | - |
| Value Creation Index ⓘ | -0.5 | -0.6 | 0.2 | 0.7 | -0.2 | 0.6 | 0.7 | 2.7 | 1.5 | -0.7 | - |
Growth Parameters ⓘGrowth Parameters Colour Code Guide ⓘ | |||||||||||
| Sales ⓘ | 48.5 | 63.2 | 72.8 | 92.9 | 111 | 137 | 179 | 222 | 311 | 282 | 305 |
| Sales YoY Gr. | - | 30.4% | 15.1% | 27.8% | 19.6% | 23.7% | 30.2% | 23.9% | 40.1% | -9.4% | - |
| Adj EPS ⓘ | 1.1 | 1 | 5.7 | 10.4 | 5 | 13.7 | 17.3 | 55.5 | 53.4 | 4.7 | 11.7 |
| YoY Gr. | - | -10.4% | 494.7% | 84.3% | -52.3% | 176.5% | 25.9% | 220.6% | -3.7% | -91.3% | - |
| BVPS (₹) ⓘ | 43.6 | 44.5 | 49.6 | 60 | 65 | 78.7 | 95.9 | 151.5 | 204.4 | 210.4 | 217.1 |
| Adj Net Profit ⓘ | 0.3 | 0.3 | 1.7 | 3.2 | 1.5 | 4.3 | 5.3 | 17.1 | 16.5 | 1.4 | 4 |
| Cash Flow from Ops. ⓘ | -0.6 | -0.4 | -3.2 | 0.1 | 2.4 | -1.3 | 4.8 | 17.5 | -9.4 | 9.4 | - |
| Debt/CF from Ops. ⓘ | -5.9 | -15.4 | -2.2 | 71.9 | 2.8 | -7.1 | 1.8 | 0.4 | -2 | 0.9 | - |
CAGR Colour Code Guide ⓘ
| 9 Years | 5 Years | 3 Years | 1 Years | |||||
|---|---|---|---|---|---|---|---|---|
| Sales ⓘ | 21.6% | 20.4% | 16.3% | -9.4% | ||||
| Adj EPS ⓘ | 17.9% | -1.3% | -35.5% | -91.3% | ||||
| BVPSⓘ | 19.1% | 26.5% | 29.9% | 2.9% | ||||
| Share Price | 33% | 35.1% | 21.5% | 21.2% | ||||
Performance Ratio Colour Code Guide ⓘ
| Mar'15 | Mar'16 | Mar'17 | Mar'18 | Mar'19 | Mar'20 | Mar'21 | Mar'22 | Mar'23 | Mar'24 | TTM | |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Return on Equity % ⓘ | 2.5 | 2.2 | 12 | 19 | 8 | 19.1 | 19.8 | 44.8 | 30 | 2.2 | 5.5 |
| Op. Profit Mgn % ⓘ | 2.4 | 1.9 | 5.1 | 6.4 | 2.9 | 4.8 | 4.8 | 10.9 | 7.7 | 0.9 | 1.4 |
| Net Profit Mgn % ⓘ | 0.7 | 0.5 | 2.4 | 3.5 | 1.4 | 3.1 | 3 | 7.7 | 5.3 | 0.5 | 1.2 |
| Debt to Equity ⓘ | 0.2 | 0.4 | 0.5 | 0.5 | 0.3 | 0.4 | 0.3 | 0.2 | 0.3 | 0.1 | - |
| Working Cap Days ⓘ | 120 | 103 | 116 | 98 | 89 | 93 | 84 | 87 | 89 | 123 | 54 |
| Cash Conv. Cycle ⓘ | 20 | 23 | 33 | 46 | 45 | 40 | 37 | 45 | 48 | 60 | 25 |
Sales growth is growing at healthy rate in last 3 years 16.30%
Sales growth is good in last 4 quarters at 11.45%
Return on Equity has declined versus last 3 years average to 5.50%
Net Profit has been subdued in last 3 years -35.46%
| Standalone | Consolidated | |
|---|---|---|
| TTM EPS (₹) | 11.7 | - |
| TTM Sales (₹ Cr.) | 305 | - |
| BVPS (₹.) ⓘ | 217.1 | - |
| Reserves (₹ Cr.) ⓘ | 64 | - |
| P/BV ⓘ | 2.13 | - |
| PE ⓘ | 39.59 | - |
| From the Market | |
|---|---|
| 52 Week Low / High (₹) | 320.00 / 646.00 |
| All Time Low / High (₹) | 0.95 / 1250.00 |
| Market Cap (₹ Cr.) | 143 |
| Equity (₹ Cr.) | 3.1 |
| Face Value (₹) | 10 |
| Industry PE ⓘ | 43 |
| Pledged * | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| PARTICULARS | Mar'15 | Mar'16 | Mar'17 | Mar'18 | Mar'19 | Mar'20 | Mar'21 | Mar'22 | Mar'23 | Mar'24 |
|---|---|---|---|---|---|---|---|---|---|---|
| Sales | 48 | 63 | 73 | 93 | 111 | 137 | 179 | 222 | 311 | 282 |
| Operating Expenses ⓘ | 47 | 62 | 69 | 87 | 108 | 131 | 170 | 198 | 287 | 279 |
| Manufacturing Costs | 1 | 2 | 2 | 2 | 2 | 2 | 3 | 4 | 4 | 4 |
| Material Costs | 43 | 56 | 63 | 82 | 103 | 126 | 164 | 190 | 278 | 270 |
| Employee Cost | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 |
| Other Costs ⓘ | 2 | 3 | 3 | 2 | 2 | 2 | 2 | 3 | 4 | 4 |
| Operating Profit ⓘ | 1 | 1 | 4 | 6 | 3 | 7 | 9 | 24 | 24 | 2 |
| Operating Profit Margin (%) | 2.4% | 1.9% | 5.1% | 6.4% | 2.9% | 4.8% | 4.8% | 10.9% | 7.7% | 0.9% |
| Other Income ⓘ | 0 | 0 | 0 | 0 | 0 | 1 | 0 | 1 | 0 | 1 |
| Interest ⓘ | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 |
| Depreciation ⓘ | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 1 | 1 | 1 |
| Exceptional Items ⓘ | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Profit Before Tax ⓘ | 0 | 0 | 3 | 5 | 2 | 6 | 7 | 24 | 23 | 3 |
| Tax ⓘ | 0 | 0 | 1 | 2 | 1 | 2 | 2 | 6 | 6 | 0 |
| Profit After Tax | 0 | 0 | 2 | 3 | 2 | 4 | 5 | 17 | 17 | 2 |
| PAT Margin (%) | 0.7% | 0.5% | 2.4% | 3.5% | 1.4% | 3.1% | 3.0% | 7.7% | 5.4% | 0.8% |
| Adjusted EPS (₹) | 1.0 | 1.0 | 5.7 | 10.4 | 5.0 | 13.7 | 17.3 | 55.6 | 53.8 | 7.0 |
| Dividend Payout Ratio (%) | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 2% | 2% | 14% |
| PARTICULARS | Mar'15 | Mar'16 | Mar'17 | Mar'18 | Mar'19 | Mar'20 | Mar'21 | Mar'22 | Mar'23 | Mar'24 |
|---|---|---|---|---|---|---|---|---|---|---|
Equity and Liabilities | ||||||||||
| Shareholders Fund | 13 | 14 | 15 | 19 | 20 | 24 | 30 | 47 | 63 | 65 |
| Share Capital ⓘ | 3 | 3 | 3 | 3 | 3 | 3 | 3 | 3 | 3 | 3 |
| Reserves ⓘ | 10 | 11 | 12 | 15 | 17 | 21 | 27 | 44 | 60 | 62 |
| Minority Interest | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Debt | 3 | 5 | 7 | 9 | 6 | 9 | 9 | 8 | 19 | 8 |
| Long Term Debt | 0 | 2 | 1 | 1 | 0 | 0 | 0 | 0 | 0 | 0 |
| Short Term Debt | 3 | 4 | 5 | 8 | 6 | 9 | 9 | 8 | 19 | 8 |
| Trade Payables | 9 | 16 | 7 | 10 | 13 | 23 | 18 | 23 | 32 | 48 |
| Others Liabilities ⓘ | 1 | 1 | 7 | 3 | 1 | 2 | 1 | 7 | 3 | 1 |
| Total Liabilities ⓘ | 26 | 36 | 36 | 41 | 40 | 58 | 57 | 85 | 117 | 122 |
Fixed Assets | ||||||||||
| Gross Block | 9 | 10 | 10 | 11 | 11 | 11 | 14 | 15 | 16 | 17 |
| Accumulated Depreciation | 2 | 3 | 3 | 4 | 4 | 4 | 5 | 5 | 6 | 6 |
| Net Fixed Assetsⓘ | 7 | 7 | 7 | 7 | 7 | 7 | 9 | 10 | 11 | 11 |
| CWIP ⓘ | 0 | 0 | 0 | 0 | 0 | 1 | 0 | 0 | 0 | 0 |
| Investmentsⓘ | 0 | 2 | 0 | 0 | 0 | 0 | 0 | 0 | 2 | 3 |
| Inventories | 4 | 6 | 7 | 7 | 8 | 19 | 11 | 12 | 33 | 21 |
| Trade Receivables | 10 | 16 | 12 | 22 | 21 | 28 | 33 | 44 | 52 | 69 |
| Cash Equivalents | 4 | 3 | 2 | 4 | 2 | 1 | 3 | 15 | 12 | 10 |
| Others Assetsⓘ | 1 | 2 | 8 | 1 | 2 | 2 | 1 | 4 | 8 | 8 |
| Total Assets ⓘ | 26 | 36 | 36 | 41 | 40 | 58 | 57 | 85 | 117 | 122 |
| PARTICULARS | Mar'15 | Mar'16 | Mar'17 | Mar'18 | Mar'19 | Mar'20 | Mar'21 | Mar'22 | Mar'23 | Mar'24 |
|---|---|---|---|---|---|---|---|---|---|---|
| Cash Flow From Operating Activity ⓘ | -1 | 0 | -3 | 0 | 2 | -1 | 5 | 17 | -9 | 9 |
| PBT ⓘ | 0 | 0 | 3 | 5 | 2 | 6 | 7 | 24 | 23 | 3 |
| Adjustment ⓘ | 1 | 1 | 1 | 1 | 1 | 1 | 2 | 1 | 2 | 0 |
| Changes in Working Capital ⓘ | -1 | -1 | -7 | -5 | 0 | -8 | -2 | -6 | -24 | 9 |
| Tax Paid ⓘ | 0 | 0 | -1 | -1 | -2 | -1 | -2 | -2 | -9 | -2 |
| Cash Flow From Investing Activity ⓘ | 0 | -2 | 1 | -2 | 2 | -2 | -3 | -1 | -3 | 0 |
| Capex | 0 | -1 | 0 | 0 | 0 | -1 | -3 | -1 | -1 | -1 |
| Net Investments | 0 | -2 | 2 | -2 | 2 | 0 | -1 | 0 | -2 | 0 |
| Others ⓘ | 0 | 0 | 0 | 0 | 0 | -1 | 1 | 0 | 0 | 0 |
| Cash Flow From Financing Activityⓘ | 0 | 2 | 1 | 2 | -4 | 2 | -2 | -2 | 10 | -11 |
| Net Proceeds from Shares ⓘ | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Net Proceeds from Borrowing ⓘ | 0 | 1 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Interest Paid ⓘ | 0 | 0 | -1 | -1 | -1 | -1 | -1 | -1 | -1 | -1 |
| Dividend Paid ⓘ | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Others ⓘ | 0 | 1 | 2 | 3 | -2 | 3 | 0 | -1 | 11 | -10 |
| Net Cash Flow ⓘ | 0 | 0 | -1 | -1 | 1 | -1 | 0 | 14 | -3 | -2 |
| PARTICULARS | Mar'15 | Mar'16 | Mar'17 | Mar'18 | Mar'19 | Mar'20 | Mar'21 | Mar'22 | Mar'23 | Mar'24 |
|---|---|---|---|---|---|---|---|---|---|---|
| Ratios | ||||||||||
| ROE (%) | 2.38 | 2.21 | 12.07 | 19.01 | 7.96 | 19.1 | 19.77 | 44.95 | 30.25 | 3.38 |
| ROCE (%) | 6.45 | 5.31 | 16.4 | 23.05 | 11.8 | 22.43 | 23.9 | 52.33 | 34.91 | 4.13 |
| Asset Turnover Ratio | 1.82 | 2.19 | 2.18 | 2.74 | 3.09 | 3.19 | 3.53 | 3.12 | 3.09 | 2.36 |
| PAT to CFO Conversion(x) | N/A | N/A | -1.5 | 0 | 1 | -0.25 | 1 | 1 | -0.53 | 4.5 | Working Capital Days |
| Receivable Days | 72 | 69 | 65 | 58 | 63 | 57 | 54 | 63 | 56 | 78 |
| Inventory Days | 42 | 27 | 29 | 24 | 22 | 31 | 27 | 20 | 26 | 34 |
| Payable Days | 99 | 81 | 68 | 40 | 41 | 52 | 45 | 39 | 36 | 54 |
Samrat Pharmachem was incorporated on June 16, 1992, at Ankleshwar in Gujarat. It was promoted by Lalit Mehta & Rajesh Mehta. The company is currently manufacturing iodine salts & bromine salts. The finished products produced by the company are used in various industries like Pharmaceuticals, Chemicals, Food, Fertilizer, Salt, etc. The products of the company are well received in Indian & foreign markets. The company is a public limited company & its shares are listed & traded on the Bombay Stock Exchange & other bourses of India. The company is presently employing 30 people for its operations at Ankleshwar & Mumbai.
The company’s manufacturing unit & test laboratory is situated in Ankleshwar. The factory is spread in an area of 3645 sq. mtrs. & has a constructed area of 20000 sq. ft. Technical innovation is their core strength. If anything is possible chemically, they strain their nerves to make it a reality. Research & Development is multi faceted focusing both on product & process development. Their commitment to keep the atmosphere beautiful & pure inspires them for further improvement in the process techniques.
The company is having a modern & well equipped quality control laboratory manned by experienced professionals who have set high standards for testing & approval. Starting with the raw materials, the intermediate stages & right upto the final stage, the products are continuously monitored for quality. The company's products & laboratory is approved by the Food & Drug Administration, Gandhinagar, Gujarat.
Samrat is well equipped to discharge its function round the year without any breakdown under adverse conditions. The company has fully computerized, centrally located office in the heart of Mumbai. Excellent documentation & personal attention to all national & international order ensures smooth & flawless logistical services. The company has well trained staff to meet any contingencies. Safe, convenient & tamper proof packaging ensures easy handling & reliability.The company is heading towards being accredited ISO 9000 & ISO 14000 Certification shortly.
The company is heading towards ERP implementation, which will integrate all the activities of the company on the internet thereby giving speedy information & reports.
Product range of the company includes:
Samrat has a major chunk of the business in Iodine & Bromine Salts. The company's customers include several multinational companies in India & Abroad. The company is exporting a part of its products to USA, Europe, Japan etc.
Achievements/ recognition :
MoneyWorks4Me rating and ranking of funds for SIP is available to subscribers only. Moneyworks4Me is not a rating and ranking agency, however it is required that users have a way of selecting funds and building a Portfolio. The method used by it are described below to enable users to understand the logic behind the rating and ranking Subscriber will find more details on this in the various content made available from time to time. In case you need more please write to besafe@moneyworks4Me.com
MoneyWorks4Me rates and ranks mutual funds based on the following data-driven system:
Funds ranking in screeners: Performance Consistency and Quality are two parameters used for ranking funds for SIP. The ranking as follows GG, GO, GR, OG, OO, OR, RG, RO and RR.
With the same color-coded funds, the one with the higher Average 3-year rolling returns (over 5 to 10 years), the number that appears in the Performance tag, ranks higher.
Here is the summary:
The third tag Upside Potential is not relevant for SIP. It is relevant for lumpsum investments in Mutual Funds.
Make an informed decision for Stocks
Invest using an intelligent system with powerful data-driven tools that help you identify opportunities and make informed buy-hold-sell decisions
Buy quality Stocks when they are available at reasonable prices and supported by an upward price trend and Sell when they are Overvalued using the Decizen Rating System. Covers 3500+ stocks
Claim your FREE 15-day access to the most practical investing handbook.
Hurry, limited to the first 10 users today!
FREE Become a savvy and confident
stock investor.
Hurry, limited to the first 10 users today!
Download APP
